论文部分内容阅读
自1990年10月～1994年7月,我们用EP和CE方案治疗晚期小细胞肺癌(Sclc)55例(均经病理学或细胞学检查证实)。按美国退伍军人医院的临床分期法分期。EP组30例中,男22例,女8例;年龄25～72岁;广泛期(ED)27例,局限期(LD)3例;初治25例,复治5例。CE组25例中,男22例,女3例;年龄25～75岁;ED期21例,LD期4例;初治21例,复治4例。两组患者的肝肾功能及心电图均正常,周围血WBC≥4×10~9/L,血小板>100×10~9/L,Karnafsky计分≥60分。
From October 1990 to July 1994, we treated 55 patients with advanced small cell lung cancer (Sclc) with EP and CE regimens (all confirmed by pathology or cytology). According to the clinical staging method of the United States Veterans Hospital. In the EP group, there were 22 males and 8 females; aged 25 to 72 years; 27 patients in the extensive period (ED) and 3 in the limited period (LD); 25 patients were initially treated and 5 were retreated. In the CE group, there were 22 males and 3 females; aged 25 to 75 years; ED phase 21 and LD phase 4; initial treatment in 21 cases and retreatment in 4 cases. The liver and kidney function and electrocardiogram were normal in both groups. Peripheral blood WBC≥4×10-9/L, platelets>100×10-9/L, Karnafsky score≥60 points.